NEW YORK – Personal Genome Diagnostics on Monday signed an agreement with Durham, North Carolina-based Almac Diagnostic Services to improve opportunities for clinical trial development and companion diagnostic projects.
As part of the agreement, the firms will provide pharma customers access to tumor profiling assays for both tissue and plasma samples, specifically PGDx elio tissue complete and PGDx elio plasma resolve.
In an email, PGDx said that it will also continue to serve its pharma partners through its laboratory services in Baltimore. The firm believes that its kit strategy will allow labs around the world to deliver standardized results and increase access, whether for clinical trial testing and companion diagnostic development or routine clinical diagnostics.
"[Almac's] longstanding reputation for providing high quality lab services to patients worldwide, along with their proven track record of implementing new technologies, make this partnership ideal," Megan Bailey, CEO of PGDx, said in a statement. "[C]ollaborating with Almac will allow us to deliver precision medicine solutions to a broader population and advance innovations in next-generation sequencing technology."
Financial details of the agreement were not disclosed.
"This collaboration with PGDx will enable Almac to provide our pharmaceutical and biotech partners with tissue and liquid biopsy options to support their translational research, clinical trials, and [companion diagnostic] development requirements," Michael Sloan, global VP of commercial operations at Almac, said in a statement. "The assay panels PGDx has developed will allow our clients to access world-class next-generation sequencing science and bioinformatics solutions."
PGDx previously signed a comarketing agreement with Genosity in September to incorporate the elio tissue complete assay in the firm's software platform and professional consulting services.